rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2025-552-558rsp-3831Research ArticleПЕРЕДОВАЯLEADING ARTICLEАутоиммунные проблемы резистентной шизофрении: уроки ревматологииAutoimmune problems of resistant schizophrenia: Lessons from rheumatologyhttps://orcid.org/0000-0002-1209-1443КаледаВ. Г.KaledaV. G.

115522, Москва, Каширское шоссе, 34

Vasily G. Kaleda

115522, Moscow, Kashirskoye Highway, 34

https://orcid.org/0009-0002-0555-3096МоховВ. Ф.MokhovV. F.

119991, Москва, Ломоносовский просп., 27/1

Vladimir F. Mokhov

119991, Moscow, Lomonosovsky avenue, 27/1

https://orcid.org/0000-0003-3001-7842ТихоновД. В.TikhonovD. V.

115522, Москва, Каширское шоссе, 34

Denis V. Tikhonov

115522, Moscow, Kashirskoye Highway, 34

https://orcid.org/0000-0002-0649-6663ЛебедеваИ. С.LebedevaI. S.

115522, Москва, Каширское шоссе, 34

115522, Moscow, Kashirskoye Highway, 34

https://orcid.org/0000-0001-6175-1076КрасноваТ. Н.KrasnovaT. N.

119991, Москва, Ломоносовский просп., 27/1

Tatiana N. Krasnova

119991, Moscow, Lomonosovsky avenue, 27/1

 

https://orcid.org/0000-0003-2641-9785БекетоваТ. В.BeketovaT. V.

Бекетова Татьяна Валентиновна

115522, Москва, Каширское шоссе, 34а; 121356, Москва, ул. Маршала Тимошенко, 15; 107023, Москва, ул. Большая Семеновская, 38

Tatiana V. Beketova

115522, Moscow, Kashirskoye Highway, 34A; 121359, Moscow, Marshala Timoshenko str., 19, building 1A; 107023, Moscow, Bolshaya Semyonovskaya str., 38

doc@tvbek.ruhttps://orcid.org/0000-0002-1598-8360НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34а

Evgeny L. Nasonov

115522, Moscow, Kashirskoye Highway, 34A

ФГБНУ «Научный центр психического здоровья»РоссияScientific Center for Mental HealthRussian FederationФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»РоссияLomonosov Moscow State UniversityRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБУ «Центральная клиническая больница с поликлиникой» Управления делами Президента Российской Федерации; ФГАОУ ВО «Московский политехнический университет»РоссияV.A. Nasonova Research Institute of Rheumatology; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation; Moscow Polytechnic UniversityRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202530122025636552558Copyright © Каледа В.Г., Мохов В.Ф., Тихонов Д.В., Лебедева И.С., Краснова Т.Н., Бекетова Т.В., Насонов Е.Л., 20252025Каледа В.Г., Мохов В.Ф., Тихонов Д.В., Лебедева И.С., Краснова Т.Н., Бекетова Т.В., Насонов Е.Л.Kaleda V.G., Mokhov V.F., Tikhonov D.V., Lebedeva I.S., Krasnova T.N., Beketova T.V., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3831

В статье рассматриваются современные представления о роли иммуно-воспалительных механизмов в развитии резистентной шизофрении. Обсуждается значение аутоиммунных реакций. Рассматриваются перспективные цели терапевтических стратегий. 

The paper is devoted to modern ideas about the role of immune-inflammatory mechanisms in the development of resistant schizophrenia. The significance of autoimmune reactions is discussed. Promising targets of therapeutic strategies are considered.

шизофрениярезистентная шизофренияиммуновоспалительные механизмыаутоиммунитетнейровоспалениеschizophreniaresistant schizophreniaimmune-inflammatory mechanismsautoimmunityneuroinflammationИсследование не имело спонсорской поддержкиReferencesTheofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-724. doi: 10.1038/ni.3731Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-724. doi: 10.1038/ni.3731Насонов ЕЛ. Современная концепция аутоиммунитета в ревматологии. Научно-практическая ревматология. 2023;61(4):397-420. doi: 10.47360/1995-4484-2023-397-420Nasonov EL. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(4):397-420 (In Russ.). doi: 10.47360/1995-4484-2023-397-420Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. J Intern Med. 2015;278(4):369-395. doi: 10.1111/joim.12395Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. J Intern Med. 2015;278(4):369-395. doi: 10.1111/joim.12395Cabrera-Maqueda JM, Planagumà J, Guasp M, Dalmau J. Autoimmune neuropsychiatric disorders manifesting with psychosis. J Clin Invest. 2025;135(20):e196507. doi: 10.1172/JCI196507Cabrera-Maqueda JM, Planagumà J, Guasp M, Dalmau J. Autoimmune neuropsychiatric disorders manifesting with psychosis. J Clin Invest. 2025;135(20):e196507. doi: 10.1172/JCI196507Shiwaku H. Autoantibodies and inflammation in schizophrenia. Psychiatry Clin Neurosci. 2025;79(10):611-618. doi: 10.1111/pcn.13872Shiwaku H. Autoantibodies and inflammation in schizophrenia. Psychiatry Clin Neurosci. 2025;79(10):611-618. doi: 10.1111/pcn.13872Клюшник ТП, Смулевич АБ, Голимбет ВЕ, Зозуля СА, Воронова ЕИ. К созданию клинико-биологической концепции шизофрении: соучастие хронического воспаления и генетической предиспозиции в формировании психопатологических расстройств. Психиатрия. 2022;20(2):6-13. doi:10.30629/2618-6667-2022-20-2-6-13Klyushnik TP, Smulevich AB, Golimbet VYe, Zozulya SA, Voronova EI. The creation of clinical and biological concept of schizophrenia: Participation of chronic inflammation and genetic predisposition in the formation of psychopathological disorders. Psychiatry (Moscow). 2022;20(2):613 (In Russ.). doi: 10.30629/2618-6667-2022-20-2-6-13Кайдан МА, Бравве ЛВ. Клинико-психопатологические особенности резистентной шизофрении. Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(2):43-50 doi: 10.17116/jnevro202512502143Kaydan MA, Bravve LV. Clinical and psychopathological features of treatment-resistant schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):43-50 (In Russ.). doi: 10.17116/jnevro202512502143Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008;77:69-77. doi: 10.1159/000112883Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom. 2008;77:69-77. doi: 10.1159/000112883Тихонов ДВ, Помыткина АН, Каледа ВГ. Современные аспекты резистентности при шизофрении. Психическое здоровье. 2021;(12):79-89. doi: 10.25557/2074-014X.2021.12.79-89Tikhonov DV, Pomytkina AN, Kaleda VG. Modern aspects of resistance in schizophrenia. Mental Health. 2021;(12): 79-89 (In Russ.). doi: 10.25557/2074-014X.2021.12.79-89Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatry. 2021;11(8):429-448. doi: 10.5498/wjp.v11.i8.429Chakrabarti S. Clozapine resistant schizophrenia: Newer avenues of management. World J Psychiatry. 2021;11(8):429-448. doi: 10.5498/wjp.v11.i8.429Ying J, Chew QH, McIntyre RS, Sim K. Treatment-resistant schizophrenia, clozapine resistance, genetic associations, and implications for precision psychiatry: A scoping review. Genes (Basel). 2023;14(3):689. doi: 10.3390/genes14030689Ying J, Chew QH, McIntyre RS, Sim K. Treatment-resistant schizophrenia, clozapine resistance, genetic associations, and implications for precision psychiatry: A scoping review. Genes (Basel). 2023;14(3):689. doi: 10.3390/genes14030689Biso L, Carli M, Scarselli M, Longoni B. Overview of novel antipsychotic drugs: State of the art, new mechanisms, and clinical aspects of promising compounds. Biomedicines. 2025;13(1):85. doi: 10.3390/biomedicines13010085Biso L, Carli M, Scarselli M, Longoni B. Overview of novel antipsychotic drugs: State of the art, new mechanisms, and clinical aspects of promising compounds. Biomedicines. 2025;13(1):85. doi: 10.3390/biomedicines13010085Detanac M, Williams C, Dragovic M, Shymko G, John AP. Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates. Aust N Z J Psychiatry. 2024;58(12):1080-1089. doi: 10.1177/00048674241274314Detanac M, Williams C, Dragovic M, Shymko G, John AP. Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates. Aust N Z J Psychiatry. 2024;58(12):1080-1089. doi: 10.1177/00048674241274314Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257. doi: 10.1016/j.nbd.2018.08.016Nucifora FC Jr, Woznica E, Lee BJ, Cascella N, Sawa A. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives. Neurobiol Dis. 2019;131:104257. doi: 10.1016/j.nbd.2018.08.016Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3-38. doi: 10.1111/j.0065-1591.2000.0ap25.xLeung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3-38. doi: 10.1111/j.0065-1591.2000.0ap25.xSzymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995;152(5):698-703. doi: 10.1176/ajp.152.5.698Szymanski S, Lieberman JA, Alvir JM, Mayerhoff D, Loebel A, Geisler S, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry. 1995;152(5):698-703. doi: 10.1176/ajp.152.5.698Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892-899. doi: 10.1093/schbul/sbu170Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al. Treatments of negative symptoms in schizophrenia: Meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41(4):892-899. doi: 10.1093/schbul/sbu170Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: New developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664-677. doi: 10.1016/S2215-0366(18)30050-6Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: New developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664-677. doi: 10.1016/S2215-0366(18)30050-6Смулевич АБ. Новая психопатологическая парадигма шизофрении и расстройств шизофренического спектра. Журнал неврологии и психиатрии им. С.С. Корсакова. 2024;124(1):7-15. doi: 10.17116/jnevro20241240117Smulevich AB. The new psychopathological paradigm of schizophrenia and schizophrenia spectrum disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):715 (In Russ.). doi: 10.17116/jnevro20241240117Kaleda V, Tikhonov D. Psychometric assessment of patients with treatment-resistant schizophrenia. Eur Psychiatry. 2024;67(Suppl 1):S749-S750. doi: 10.1192/j.eurpsy.2024.1560Kaleda V, Tikhonov D. Psychometric assessment of patients with treatment-resistant schizophrenia. Eur Psychiatry. 2024;67(Suppl 1):S749-S750. doi: 10.1192/j.eurpsy.2024.1560Monteleone P, Cascino G, Rossi A, Rocca P, Bertolino A, Aguglia E, et al.; Italian Network for Research on Psychoses. Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study. Schizophr Res. 2022;248:279-286. doi: 10.1016/j.schres.2022.08.015Monteleone P, Cascino G, Rossi A, Rocca P, Bertolino A, Aguglia E, et al.; Italian Network for Research on Psychoses. Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study. Schizophr Res. 2022;248:279-286. doi: 10.1016/j.schres.2022.08.015Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, et al. Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14(3):238. doi: 10.3390/ph14030238Carli M, Kolachalam S, Longoni B, Pintaudi A, Baldini M, Aringhieri S, et al. Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals (Basel). 2021;14(3):238. doi: 10.3390/ph14030238Schmidt-Kastner R, Guloksuz S, Kietzmann T, van Os J, Rutten BPF. Mutation-intolerant genes and monogenic disease genes in 145 loci of schizophrenia (SCZ) GWAS are linked to the ischemia-hypoxia response. Schizophr Bull. 2019;45(Suppl 2):S342-S343. doi: 10.1093/schbul/sbz020.639Schmidt-Kastner R, Guloksuz S, Kietzmann T, van Os J, Rutten BPF. Mutation-intolerant genes and monogenic disease genes in 145 loci of schizophrenia (SCZ) GWAS are linked to the ischemia-hypoxia response. Schizophr Bull. 2019;45(Suppl 2):S342-S343. doi: 10.1093/schbul/sbz020.639Дудина АН, Тихонов ДВ, Вершинина ОЮ, Каледа ВГ, Лебедева ИС. Структурная МРТ головного мозга при терапевтически резистентной шизофрении. Психиатрия. 2024;22(1):15-25. doi: 10.30629/2618-6667-2024-22-1-15-25Dudina AN, Tikhonov DV, Vershinina OYu, Kaleda VG, Lebedeva IS. Structural MRI of the brain in treatment-resistant schizophrenia. Psychiatry (Moscow). 2024;22(1):15-25 (In Russ.). doi: 10.30629/2618-6667-2024-22-1-15-25Itahashi T, Noda Y, Iwata Y, Tarumi R, Tsugawa S, Plitman E, et al. Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. Neuroimage Clin. 2021;32:102852. doi: 10.1016/j.nicl.2021.102852Itahashi T, Noda Y, Iwata Y, Tarumi R, Tsugawa S, Plitman E, et al. Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. Neuroimage Clin. 2021;32:102852. doi: 10.1016/j.nicl.2021.102852Huang H, Qin X, Xu R, Xiong Y, Hao K, Chen C, et al. Default mode network, disorganization, and treatment-resistant schizophrenia. Schizophr Bull. 2025 Mar 3:sbaf018. doi: 10.1093/schbul/sbaf018Huang H, Qin X, Xu R, Xiong Y, Hao K, Chen C, et al. Default mode network, disorganization, and treatment-resistant schizophrenia. Schizophr Bull. 2025 Mar 3:sbaf018. doi: 10.1093/schbul/sbaf018Matrone M, Kotzalidis GD, Romano A, Bozzao A, Cuomo I, Valente F, et al. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between earlyand adult-onset patients. Prog Neuropsychopharmacol Biol Psychiatry. 2022;114:110493. doi: 10.1016/j.pnpbp.2021.110493Matrone M, Kotzalidis GD, Romano A, Bozzao A, Cuomo I, Valente F, et al. Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between earlyand adult-onset patients. Prog Neuropsychopharmacol Biol Psychiatry. 2022;114:110493. doi: 10.1016/j.pnpbp.2021.110493Chen W, Gou M, Wang L, Li N, Li W, Tong J, et al. Inflammatory disequilibrium and lateral ventricular enlargement in treatmentresistant schizophrenia. Eur Neuropsychopharmacol. 2023;72:18-29. doi: 10.1016/j.euroneuro.2023.03.014Chen W, Gou M, Wang L, Li N, Li W, Tong J, et al. Inflammatory disequilibrium and lateral ventricular enlargement in treatmentresistant schizophrenia. Eur Neuropsychopharmacol. 2023;72:18-29. doi: 10.1016/j.euroneuro.2023.03.014Gou M, Li W, Tong J, Zhou Y, Xie T, Yu T, et al. Correlation of Immune-Inflammatory Response System (IRS)/Compensatory Immune-Regulatory Reflex System (CIRS) with white matter integrity in first-episode patients with schizophrenia. Mol Neurobiol. 2024;61(5):2754-2763. doi: 10.1007/s12035-023-03694-0Gou M, Li W, Tong J, Zhou Y, Xie T, Yu T, et al. Correlation of Immune-Inflammatory Response System (IRS)/Compensatory Immune-Regulatory Reflex System (CIRS) with white matter integrity in first-episode patients with schizophrenia. Mol Neurobiol. 2024;61(5):2754-2763. doi: 10.1007/s12035-023-03694-0Saccaro LF, Crokaert J, Perroud N, Piguet C. Structural and functional MRI correlates of inflammation in bipolar disorder: A systematic review. J Affect Disord. 2023;325:83-92. doi: 10.1016/j.jad.2022.12.162Saccaro LF, Crokaert J, Perroud N, Piguet C. Structural and functional MRI correlates of inflammation in bipolar disorder: A systematic review. J Affect Disord. 2023;325:83-92. doi: 10.1016/j.jad.2022.12.162Nayak U, Manikkath J, Arora D, Mudgal J. Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: An update. Metab Brain Dis. 2025;40(2):119. doi: 10.1007/s11011-025-01548-3Nayak U, Manikkath J, Arora D, Mudgal J. Impact of neuroinflammation on brain glutamate and dopamine signalling in schizophrenia: An update. Metab Brain Dis. 2025;40(2):119. doi: 10.1007/s11011-025-01548-3Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: Theoretical underpinnings in schizophrenia. Front Pharmacol. 2012;3(1):195. doi: 10.3389/fphar.2012.00195Schwartz TL, Sachdeva S, Stahl SM. Glutamate neurocircuitry: Theoretical underpinnings in schizophrenia. Front Pharmacol. 2012;3(1):195. doi: 10.3389/fphar.2012.00195Liu J, Zhao W, Wang Y. Lights and shadows of clozapine on the immune system in schizophrenia: A narrative literature review. Metab Brain Dis. 2025;40(2):128. doi: 10.1007/s11011-02501558-1Liu J, Zhao W, Wang Y. Lights and shadows of clozapine on the immune system in schizophrenia: A narrative literature review. Metab Brain Dis. 2025;40(2):128. doi: 10.1007/s11011-02501558-1Miller BJ, Goldsmith DR. Evaluating the hypothesis that schizophrenia is an inflammatory disorder. Focus (Am Psychiatr Publ). 2020;18(4):391-401. doi: 10.1176/appi.focus.20200015Miller BJ, Goldsmith DR. Evaluating the hypothesis that schizophrenia is an inflammatory disorder. Focus (Am Psychiatr Publ). 2020;18(4):391-401. doi: 10.1176/appi.focus.20200015Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry. 2014;75(4):300-6. doi: 10.1016/j.biopsych.2013.09.023Benros ME, Eaton WW, Mortensen PB. The epidemiologic evidence linking autoimmune diseases and psychosis. Biol Psychiatry. 2014;75(4):300-6. doi: 10.1016/j.biopsych.2013.09.023Jeppesen R, Benros ME. Autoimmune diseases and psychotic disorders. Front Psychiatry. 2019;10:131. doi: 10.3389/fpsyt.2019.00131Jeppesen R, Benros ME. Autoimmune diseases and psychotic disorders. Front Psychiatry. 2019;10:131. doi: 10.3389/fpsyt.2019.00131Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. Am J Psychiatry. 2011;168(12):1303-1310. doi: 10.1176/appi.ajp.2011.11030516Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: A 30-year population-based register study. Am J Psychiatry. 2011;168(12):1303-1310. doi: 10.1176/appi.ajp.2011.11030516Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638-646. doi: 10.1111/j.1399-5618.2010.00853.xEaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord. 2010;12(6):638-646. doi: 10.1111/j.1399-5618.2010.00853.xChen SJ, Chao YL, Chen CY, Chang CM, Wu EC, Wu CS, et al. Prevalence of autoimmune diseases in in-patients with schizophrenia: Nationwide population-based study. Br J Psychiatry. 2012;200(5):374-380. doi: 10.1192/bjp.bp.111.092098Chen SJ, Chao YL, Chen CY, Chang CM, Wu EC, Wu CS, et al. Prevalence of autoimmune diseases in in-patients with schizophrenia: Nationwide population-based study. Br J Psychiatry. 2012;200(5):374-380. doi: 10.1192/bjp.bp.111.092098Sá ZC, Buinho A, Oliveira T, Soares FR, Rema JP, Novais F. Neuroinflamation treatment options in resistant schizophrenia – State of the art. Curr Treat Options Psych. 2025:12(26). doi: 10.1007/s40501-025-00356-xSá ZC, Buinho A, Oliveira T, Soares FR, Rema JP, Novais F. Neuroinflamation treatment options in resistant schizophrenia – State of the art. Curr Treat Options Psych. 2025:12(26). doi: 10.1007/s40501-025-00356-xFontes H, Nzwalo H, Mendes S, Fernandes S, Ponte G, Pereira M. Central nervous system vasculitis presenting as acute psychotic disorder. Eur Psychiatry. 2011;26(S2):745-745. doi: 10.1016/S0924-9338(11)72450-6Fontes H, Nzwalo H, Mendes S, Fernandes S, Ponte G, Pereira M. Central nervous system vasculitis presenting as acute psychotic disorder. Eur Psychiatry. 2011;26(S2):745-745. doi: 10.1016/S0924-9338(11)72450-6Бекетова ТВ, Коновалов РН. Синдром Сусака (ретино-кохлеоцеребральная васкулопатия). Научно-практическая ревматология. 2018;56(2):249-252. doi: 10.14412/1995-4484-2018-249-252Beketova TV, Konovalov RN. Susac’s syndrome (retinocochleocerebral vasculopathy). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(2): 249-252 (In Russ.). doi: 10.14412/1995-4484-2018-249-252Gasparinho R, Fernandes N, Martins M, Santos N, Ferreira LP, Alho A. Psychosis as the first manifestation of granulomatosis with polyangiitis – A case report. Psychiatr Danub. 2022;34(2):315-317. doi: 10.24869/psyd.2022.315Gasparinho R, Fernandes N, Martins M, Santos N, Ferreira LP, Alho A. Psychosis as the first manifestation of granulomatosis with polyangiitis – A case report. Psychiatr Danub. 2022;34(2):315-317. doi: 10.24869/psyd.2022.315Duarte EV, Suárez GP, Hernández SV, Beltrán JC. Psicosis y alteraciones en la sensopercepción como manifestaciones atípicas de la poliangitis microscópica. Revista Colombiana de Reumatología. 2020;27(2):135-140. doi: 10.1016/j.rcreue.2019.04.008Duarte EV, Suárez GP, Hernández SV, Beltrán JC. Psicosis y alteraciones en la sensopercepción como manifestaciones atípicas de la poliangitis microscópica. Revista Colombiana de Reumatología. 2020;27(2):135-140. doi: 10.1016/j.rcreue.2019.04.008Patel P, Steinschneider M, Boneparth A, Lantos G. Neuro-Behçet disease presenting with acute psychosis in an adolescent. J Child Neurol. 2014;29(9):NP86-NP91. doi: 10.1177/0883073813504137Patel P, Steinschneider M, Boneparth A, Lantos G. Neuro-Behçet disease presenting with acute psychosis in an adolescent. J Child Neurol. 2014;29(9):NP86-NP91. doi: 10.1177/0883073813504137Lin CE. One patient with Sjogren’s syndrome presenting schizophrenia-like symptoms. Neuropsychiatr Dis Treat. 2016;12:661-663. doi: 10.2147/NDT.S97753Lin CE. One patient with Sjogren’s syndrome presenting schizophrenia-like symptoms. Neuropsychiatr Dis Treat. 2016;12:661-663. doi: 10.2147/NDT.S97753Hajjaj I, Adali I, Idrissi Ouali M, Kissani N. Un accès psychotique aigu révélateur d’un neurolupus avec images atypiques à l’IRM encéphalique [An acute psychotic episode revealing neuropsychiatric lupus with atypical brain MRI]. Encephale. 2012;38(6):519-523 (In French). doi: 10.1016/j.encep.2012.04.004Hajjaj I, Adali I, Idrissi Ouali M, Kissani N. Un accès psychotique aigu révélateur d’un neurolupus avec images atypiques à l’IRM encéphalique [An acute psychotic episode revealing neuropsychiatric lupus with atypical brain MRI]. Encephale. 2012;38(6):519-523 (In French). doi: 10.1016/j.encep.2012.04.004Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1992;19(1):47-52.Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1992;19(1):47-52.Пизова НВ. Неврологические и психические расстройства при системной красной волчанке. Журнал неврологии и психиатрии им. С.С. Корсакова. 2010;110(8):76-83.Pizova NV. Neuropsychiatric disorders in systemic lupus erythematosus. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(8):76-83 (In Russ.).Ganguli R, Rabin BS, Kelly RH, Lyte M, Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann N Y Acad Sci. 1987;496:676-685. doi: 10.1111/j.1749-6632.1987.tb35829.xGanguli R, Rabin BS, Kelly RH, Lyte M, Ragu U. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann N Y Acad Sci. 1987;496:676-685. doi: 10.1111/j.1749-6632.1987.tb35829.xTanaka S, Matsunaga H, Kimura M, Tatsumi Ki, Hidaka Y, Takano T, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 2003;141(12):155-164. doi: 10.1016/s0165-5728(03)00252-2Tanaka S, Matsunaga H, Kimura M, Tatsumi Ki, Hidaka Y, Takano T, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol. 2003;141(12):155-164. doi: 10.1016/s0165-5728(03)00252-2Laske C, Zank M, Klein R, Stransky E, Batra A, Buchkremer G, Schott K. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res. 2008;158(1):83-86. doi: 10.1016/j.psychres.2006.04.023Laske C, Zank M, Klein R, Stransky E, Batra A, Buchkremer G, Schott K. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res. 2008;158(1):83-86. doi: 10.1016/j.psychres.2006.04.023Schott K, Schaefer JE, Richartz E, Batra A, Eusterschulte B, Klein R, et al. Autoantibodies to serotonin in serum of patients with psychiatric disorders. Psychiatry Res. 2003;121(1):51-57. doi: 10.1016/s0165-1781(03)00137-9Schott K, Schaefer JE, Richartz E, Batra A, Eusterschulte B, Klein R, et al. Autoantibodies to serotonin in serum of patients with psychiatric disorders. Psychiatry Res. 2003;121(1):51-57. doi: 10.1016/s0165-1781(03)00137-9Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res. 2013;150(1):245-251. doi: 10.1016/j.schres.2013.07.029Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res. 2013;150(1):245-251. doi: 10.1016/j.schres.2013.07.029van Mierlo HC, de Witte L, Derksen RH, Otten HG; GROUP investigators. The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: Results from a large cohort study. NPJ Schizophr. 2015;1:15013. doi: 10.1038/npjschz.2015.13van Mierlo HC, de Witte L, Derksen RH, Otten HG; GROUP investigators. The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: Results from a large cohort study. NPJ Schizophr. 2015;1:15013. doi: 10.1038/npjschz.2015.13Alarcón-Segovia D, Fishbein E, Cetina JA, Raya RJ, Barrera E. Antigenic specificity of chlorpromazine-induced antinuclear antibodies. Clin Exp Immunol. 1973;15(4):543-548.Alarcón-Segovia D, Fishbein E, Cetina JA, Raya RJ, Barrera E. Antigenic specificity of chlorpromazine-induced antinuclear antibodies. Clin Exp Immunol. 1973;15(4):543-548.Heath RG, Krupp IM. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques. Arch Gen Psychiatry. 1967;16(1):1-9. doi: 10.1001/archpsyc.1967.01730190003001Heath RG, Krupp IM. Schizophrenia as an immunologic disorder. I. Demonstration of antibrain globulins by fluorescent antibody techniques. Arch Gen Psychiatry. 1967;16(1):1-9. doi: 10.1001/archpsyc.1967.01730190003001Heath RG, Krupp IM. Catatonia induced in monkeys by antibrain antibody. Am J Psychiatry. 1967;123(12):1499-1504. doi: 10.1176/ajp.123.12.1499Heath RG, Krupp IM. Catatonia induced in monkeys by antibrain antibody. Am J Psychiatry. 1967;123(12):1499-1504. doi: 10.1176/ajp.123.12.1499Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis in psychiatry. Curr Psychiatry Rev. 2011;7(3):189-193. doi: 10.2174/1573400117971831849Kayser MS, Dalmau J. Anti-NMDA receptor encephalitis in psychiatry. Curr Psychiatry Rev. 2011;7(3):189-193. doi: 10.2174/1573400117971831849Yucel Y, Sidow NO, Yilmaz A. Approach and overview of autoimmune encephalitis: A review. Medicine (Baltimore). 2025;104(21):e42472. doi: 10.1097/MD.0000000000042472Yucel Y, Sidow NO, Yilmaz A. Approach and overview of autoimmune encephalitis: A review. Medicine (Baltimore). 2025;104(21):e42472. doi: 10.1097/MD.0000000000042472Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839-887. doi: 10.1152/physrev.00010.2016Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell surface proteins in autoimmune diseases of the central nervous system. Physiol Rev. 2017;97(2):839-887. doi: 10.1152/physrev.00010.2016Ramirez-Bermudez J, Espinola-Nadurille M, Restrepo-Martinez M, Martínez-Ángeles V, Martínez-Carrillo F, Cascante L, et al. Autoimmune psychosis: Psychopathological patterns and outcome after immunotherapy. Schizophr Res. 2025;281:10-19. doi: 10.1016/j.schres.2025.04.024Ramirez-Bermudez J, Espinola-Nadurille M, Restrepo-Martinez M, Martínez-Ángeles V, Martínez-Carrillo F, Cascante L, et al. Autoimmune psychosis: Psychopathological patterns and outcome after immunotherapy. Schizophr Res. 2025;281:10-19. doi: 10.1016/j.schres.2025.04.024Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: A systematic review and meta-analysis. Psychol Med. 2014;44(12):2475-2487. doi: 10.1017/S003329171300295XPollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: A systematic review and meta-analysis. Psychol Med. 2014;44(12):2475-2487. doi: 10.1017/S003329171300295XShiwaku H, Katayama S, Kondo K, Nakano Y, Tanaka H, Yoshioka Y, et al. Autoantibodies against NCAM1 from patients with schizophrenia cause schizophrenia-related behavior and changes in synapses in mice. Cell Rep Med. 2022;3(4):100597. doi: 10.1016/j.xcrm.2022.100597Shiwaku H, Katayama S, Kondo K, Nakano Y, Tanaka H, Yoshioka Y, et al. Autoantibodies against NCAM1 from patients with schizophrenia cause schizophrenia-related behavior and changes in synapses in mice. Cell Rep Med. 2022;3(4):100597. doi: 10.1016/j.xcrm.2022.100597Shiwaku H, Katayama S, Gao M, Kondo K, Nakano Y, Motokawa Y, et al. Analyzing schizophrenia-related phenotypes in mice caused by autoantibodies against NRXN1α in schizophrenia. Brain Behav Immun. 2023;111:32-45. doi: 10.1016/j.bbi.2023.03.028Shiwaku H, Katayama S, Gao M, Kondo K, Nakano Y, Motokawa Y, et al. Analyzing schizophrenia-related phenotypes in mice caused by autoantibodies against NRXN1α in schizophrenia. Brain Behav Immun. 2023;111:32-45. doi: 10.1016/j.bbi.2023.03.028Клюшник ТП, Зозуля СА. Иммунология шизофрении: современный взгляд на воспалительные гипотезы заболевания. Психиатрия. 2024;22(4):14-25. doi: 10.30629/2618-6667-2024-22-4-14-25Klyushnik TP, Zozulya SA. Immunology of schizophrenia: A modern view on inflammatory hypotheses of the disease. Psychiatry (Moscow). 2024;22(4):14-25 (In Russ.). doi: 10.30629/2618-6667-2024-22-4-14-25Patlola SR, Holleran L, Dauvermann MR, Rokita K, Laighneach A, Hallahan B, et al. Investigating the relationship between Toll-like receptor activity, low-grade inflammation and cognitive deficits in schizophrenia patients – A mediation analysis. Brain Behav Immun. 2025;128:529-539. doi: 10.1016/j.bbi.2025.04.024Patlola SR, Holleran L, Dauvermann MR, Rokita K, Laighneach A, Hallahan B, et al. Investigating the relationship between Toll-like receptor activity, low-grade inflammation and cognitive deficits in schizophrenia patients – A mediation analysis. Brain Behav Immun. 2025;128:529-539. doi: 10.1016/j.bbi.2025.04.024Zhu Y, Webster MJ, Walker AK, Massa P, Middleton FA, Weickert CS. Increased prefrontal cortical cells positive for macrophage/ microglial marker CD163 along blood vessels characterizes a neuropathology of neuroinflammatory schizophrenia. Brain Behav Immun. 2023;111:46-60. doi: 10.1016/j.bbi.2023.03.018Zhu Y, Webster MJ, Walker AK, Massa P, Middleton FA, Weickert CS. Increased prefrontal cortical cells positive for macrophage/ microglial marker CD163 along blood vessels characterizes a neuropathology of neuroinflammatory schizophrenia. Brain Behav Immun. 2023;111:46-60. doi: 10.1016/j.bbi.2023.03.018Zhilyaeva TV, Rukavishnikov GV, Manakova EA, Mazo GE. Serum interleukin-6 in schizophrenia: Associations with clinical and sociodemographic characteristics. Consort Psychiatr. 2023;4(4):5-16. doi: 10.17816/CP11067Zhilyaeva TV, Rukavishnikov GV, Manakova EA, Mazo GE. Serum interleukin-6 in schizophrenia: Associations with clinical and sociodemographic characteristics. Consort Psychiatr. 2023;4(4):5-16. doi: 10.17816/CP11067Shnayder NA, Khasanova AK, Strelnik AI, Al-Zamil M, Otmakhov AP, Neznanov NG, et al. Cytokine imbalance as a biomarker of treatment-resistant schizophrenia. Int J Mol Sci. 2022;23(19):11324. doi: 10.3390/ijms231911324Shnayder NA, Khasanova AK, Strelnik AI, Al-Zamil M, Otmakhov AP, Neznanov NG, et al. Cytokine imbalance as a biomarker of treatment-resistant schizophrenia. Int J Mol Sci. 2022;23(19):11324. doi: 10.3390/ijms231911324Leboyer M, Godin O, Terro E, Boukouaci W, Lu CL, Andre M, et al.; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups. Immune signatures of treatmentresistant schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) study. Schizophr Bull Open. 2021;2(1):sgab012. doi: 10.1093/schizbullopen/sgab012Leboyer M, Godin O, Terro E, Boukouaci W, Lu CL, Andre M, et al.; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups. Immune signatures of treatmentresistant schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) study. Schizophr Bull Open. 2021;2(1):sgab012. doi: 10.1093/schizbullopen/sgab012Szota AM, Ćwiklińska-Jurkowska M, Radajewska I, Lis K, Grudzka P, Dróżdż W. Effect of electroconvulsive therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and soluble IL-2 receptor in treatment-resistant schizophrenia (TRS) patients – A preliminary study. J Clin Med. 2025;14(9):3170. doi: 10.3390/jcm14093170Szota AM, Ćwiklińska-Jurkowska M, Radajewska I, Lis K, Grudzka P, Dróżdż W. Effect of electroconvulsive therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and soluble IL-2 receptor in treatment-resistant schizophrenia (TRS) patients – A preliminary study. J Clin Med. 2025;14(9):3170. doi: 10.3390/jcm14093170He J, Li J, Wei Y, He Z, Liu J, Yuan N, et al. Multiple serum antiglutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia. BMC Psychiatry. 2024;24(1):248. doi: 10.1186/s12888-024-05689-0He J, Li J, Wei Y, He Z, Liu J, Yuan N, et al. Multiple serum antiglutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia. BMC Psychiatry. 2024;24(1):248. doi: 10.1186/s12888-024-05689-0Tong J, Zhou Y, Huang J, Zhang P, Fan F, Chen S, et al. N-methyl-D-aspartate receptor antibody and white matter deficits in schizophrenia treatment-resistance. Schizophr Bull. 2021;47(5):1463-1472. doi: 10.1093/schbul/sbab003Tong J, Zhou Y, Huang J, Zhang P, Fan F, Chen S, et al. N-methyl-D-aspartate receptor antibody and white matter deficits in schizophrenia treatment-resistance. Schizophr Bull. 2021;47(5):1463-1472. doi: 10.1093/schbul/sbab003Hoprekstad GE, Johnsen E, Bartz-Johannessen C, Bjarke JK, Drosos P, Fasmer OB, et al. Prednisolone add-on in early phase schizophrenia: A randomized, double-blind, placebo-controlled pilot study. Brain Behav Immun Health. 2025;48:101047. doi: 10.1016/j.bbih.2025.101047Hoprekstad GE, Johnsen E, Bartz-Johannessen C, Bjarke JK, Drosos P, Fasmer OB, et al. Prednisolone add-on in early phase schizophrenia: A randomized, double-blind, placebo-controlled pilot study. Brain Behav Immun Health. 2025;48:101047. doi: 10.1016/j.bbih.2025.101047Girgis RR, Ciarleglio A, Choo T, Haynes G, Bathon JM, Cremers S, et al. A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology. 2018;43(6):1317-1323. doi: 10.1038/npp.2017.258Girgis RR, Ciarleglio A, Choo T, Haynes G, Bathon JM, Cremers S, et al. A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology. 2018;43(6):1317-1323. doi: 10.1038/npp.2017.258Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. doi: 10.1001/2013.jamapsychiatry.4Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41. doi: 10.1001/2013.jamapsychiatry.4Weickert TW, Jacomb I, Lenroot R, Lappin J, Weinberg D, Brooks WS, et al. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial. Brain Behav Immun. 2024;115:191-200. doi: 10.1016/j.bbi.2023.10.012Weickert TW, Jacomb I, Lenroot R, Lappin J, Weinberg D, Brooks WS, et al. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial. Brain Behav Immun. 2024;115:191-200. doi: 10.1016/j.bbi.2023.10.012Bejerot S, Sigra Stein S, Welin E, Eklund D, Hylén U, Humble MB. Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two openlabel pilot studies on treatment-resistant patients. J Psychiatr Res. 2023;158:319-329. doi: 10.1016/j.jpsychires.2022.12.003Bejerot S, Sigra Stein S, Welin E, Eklund D, Hylén U, Humble MB. Rituximab as an adjunctive treatment for schizophrenia spectrum disorder or obsessive-compulsive disorder: Two openlabel pilot studies on treatment-resistant patients. J Psychiatr Res. 2023;158:319-329. doi: 10.1016/j.jpsychires.2022.12.003Насонов ЕЛ, Бекетова ТВ, Ананьева ЛП, Васильев ВИ, Соловьев СК, Авдеева АС. Перспективы анти-В-клеточной терапии при иммуно-воспалительных ревматических заболеваниях. Научно-практическая ревматология. 2019;57:1-40. doi: 10.14412/1995-4484-2019-3-40Nasonov EL, Beketova TV, Ananyeva LP, Vasilyev VI, Solovyev SK, Avdeeva AS. Prospects for anti-B-cell therapy in immuno-inflammatory rheumatic diseases. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57:1-40 (In Russ.). doi: 10.14412/1995-4484-2019-3-40Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470-475. doi: 10.1136/ard.2006.057885Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470-475. doi: 10.1136/ard.2006.057885Rodziewicz M, Dyball S, David T, Sutton E, Parker B, Bruce IN. The effectiveness of rituximab in the real-world treatment of neuropsychiatric SLE: Results from the British Iles Lupus Assessment Group Biologics Register (BILAG-BR). Ann Rheum Dis. 2024;83:137-138. doi: 10.1136/annrheumdis-2024-eular.4840Rodziewicz M, Dyball S, David T, Sutton E, Parker B, Bruce IN. The effectiveness of rituximab in the real-world treatment of neuropsychiatric SLE: Results from the British Iles Lupus Assessment Group Biologics Register (BILAG-BR). Ann Rheum Dis. 2024;83:137-138. doi: 10.1136/annrheumdis-2024-eular.4840Angeletti A, Baraldi O, Chiocchini AL, Comai G, Cravedi P, La Manna G. Rituximab as first-line therapy in severe lupus erythematosus with neuropsychiatric and renal involvement: A casereport and review of the literature. J Clin Case Rep. 2017;7(10):1033. doi: 10.4172/2165-7920.10001033Angeletti A, Baraldi O, Chiocchini AL, Comai G, Cravedi P, La Manna G. Rituximab as first-line therapy in severe lupus erythematosus with neuropsychiatric and renal involvement: A casereport and review of the literature. J Clin Case Rep. 2017;7(10):1033. doi: 10.4172/2165-7920.10001033Wang H, Zhao L, Yang S, Ding H, Wu W, Yu L, et al. Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus. Front Immunol. 2025;16:1599473. doi: 10.3389/fimmu.2025.1599473Wang H, Zhao L, Yang S, Ding H, Wu W, Yu L, et al. Rituximab as the first-line treatment in newly diagnosed systemic lupus erythematosus. Front Immunol. 2025;16:1599473. doi: 10.3389/fimmu.2025.1599473Griffiths K, Mellado MR, Chung R, Lally J, McQueen G, Sendt KV, et al. Changes in immunoglobulin levels during clozapine treatment in schizophrenia. Brain Behav Immun. 2024;115:223-228. doi: 10.1016/j.bbi.2023.10.001Griffiths K, Mellado MR, Chung R, Lally J, McQueen G, Sendt KV, et al. Changes in immunoglobulin levels during clozapine treatment in schizophrenia. Brain Behav Immun. 2024;115:223-228. doi: 10.1016/j.bbi.2023.10.001Ota VK, Spindola LM, Stavrum AK, Costa GO, Bugiga AVG, Noto MN, et al. Longitudinal DNA methylation and cell-type proportions alterations in risperidone treatment response in firstepisode psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2025;139:111402. doi: 10.1016/j.pnpbp.2025.111402Ota VK, Spindola LM, Stavrum AK, Costa GO, Bugiga AVG, Noto MN, et al. Longitudinal DNA methylation and cell-type proportions alterations in risperidone treatment response in firstepisode psychosis. Prog Neuropsychopharmacol Biol Psychiatry. 2025;139:111402. doi: 10.1016/j.pnpbp.2025.111402Boukouaci W, Lajnef M, Wu CL, Bouassida J, Saitoh K, Sugunasabesan S, et al. B cell-activating factor (BAFF): A promising transnosographic biomarker of inflammation and autoimmunity in bipolar disorder and schizophrenia. Brain Behav Immun. 2024;121:178-188. doi: 10.1016/j.bbi.2024.07.025Boukouaci W, Lajnef M, Wu CL, Bouassida J, Saitoh K, Sugunasabesan S, et al. B cell-activating factor (BAFF): A promising transnosographic biomarker of inflammation and autoimmunity in bipolar disorder and schizophrenia. Brain Behav Immun. 2024;121:178-188. doi: 10.1016/j.bbi.2024.07.025Li L, Shen S, Shao S, Dang E, Wang G, Fang H, et al. The role of B cell-activating factor system in autoimmune diseases: Mechanisms, disease implications, and therapeutic advances. Front Immunol. 2025;16:1538555. doi: 10.3389/fimmu.2025.1538555Li L, Shen S, Shao S, Dang E, Wang G, Fang H, et al. The role of B cell-activating factor system in autoimmune diseases: Mechanisms, disease implications, and therapeutic advances. Front Immunol. 2025;16:1538555. doi: 10.3389/fimmu.2025.1538555Насонов ЕЛ, Попкова ТВ, Лила АМ. Белимумаб в лечении системной красной волчанки: 20 лет фундаментальных исследований, 10 лет клинической практики. Научно-практическая ревматология. 2021;59(4):367-383. doi: 10.47360/1995-4484-2021-367-383Nasonov EL, Popkova TV, Lila AM. Belimumab in the treatment of systemic lupus erythematosus: 20 years of basic research, 10 years of clinical practice. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(4):367-383 (In Russ.). doi: 10.47360/1995-4484-2021-367-383Насонов ЕЛ, Румянцев АГ, Самсонов МЮ. Фармакотерапия аутоиммунных ревматических заболеваний – от моноклональных антител к CAR-T-клеткам: 20 лет спустя. Научно-практическая ревматология. 2024;62(3):262-279. doi: 10.47360/1995-4484-2024-262-279Nasonov EL, Rumyantsev AG, Samsonov MYu. Pharmacotherapy of autoimmune rheumatic diseases – From monoclonal antibodies to CAR T cells: 20 years later. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(3):262-279 (In Russ.). doi: 10.47360/1995-4484-2024-262-279

The authors declare that there are no conflicts of interest present.